Search Results - "Targher, G."

Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens by Targher, G.

“…Non‐alcoholic fatty liver disease (NAFLD) affects a substantial proportion of the general population and is frequently associated with many features of the…”
Get full text

Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? by Targher, G., Marra, F., Marchesini, G.

“…Non-alcoholic fatty liver disease (NAFLD), comprising a spectrum of conditions ranging from pure steatosis to steatohepatitis and cirrhosis, has reached…”
Get full text

Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials by Mantovani, A., Byrne, C.D., Scorletti, E., Mantzoros, C.S., Targher, G.

“…There are no approved drugs for the treatment of non-alcoholic fatty liver disease (NAFLD). However, many randomized controlled trials (RCT) have examined the…”
Get full text

Global epidemiology of nonalcoholic fatty liver disease: Meta‐analytic assessment of prevalence, incidence, and outcomes by Lonardo, A., Byrne, C.D., Caldwell, S.H., Cortez‐Pinto, H., Targher, G.

Get full text

Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies by Bellinato, F., Gisondi, P., Mantovani, A., Girolomoni, G., Targher, G.

“…Purpose Chronic plaque psoriasis is associated with the presence of non-alcoholic fatty liver disease (NAFLD), but the magnitude of this association remains…”
Get full text

Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon? by Targher, G, Marchesini, G, Byrne, C.D

“…Abstract Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liver-related…”
Get full text

Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link? by Targher, G., Lonardo, A., Rossini, M.

“…Purpose Liver diseases are associated with decreased bone mineral density (BMD) and evidence suggests that nonalcoholic fatty liver disease (NAFLD) affects…”
Get full text

Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients by Targher, G, Bertolini, L, Rodella, S, Zoppini, G, Lippi, G, Day, C, Muggeo, M

“…Aims/hypothesis Non-alcoholic fatty liver disease (NAFLD) is associated with an increased risk of cardiovascular disease in type 2 diabetes. Currently, there…”
Get full text

Patients with diabetes are at higher risk for severe illness from COVID-19 by Targher, G., Mantovani, A., Wang, X.-B., Yan, H.-D., Sun, Q.-F., Pan, K.-H., Byrne, C.D., Zheng, K.I., Chen, Y.-P., Eslam, M., George, J., Zheng, M.-H.

“…•It is currently uncertain whether people with diabetes are at higher risk of severe illness from coronavirus disease 2019 (COVID-19).•We found that diabetes…”
Get full text

Mortality from infectious diseases in diabetes by Zoppini, G., Fedeli, U., Schievano, E., Dauriz, M., Targher, G., Bonora, E., Corti, M.C.

“…To investigate the risk of mortality from infections by comparing the underlying causes of death versus the multiple causes of death in known diabetic subjects…”
Get full text

Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes by Mantovani, A., Turino, T., Lando, M.G., Gjini, K., Byrne, C.D., Zusi, C., Ravaioli, F., Colecchia, A., Maffeis, C., Salvagno, G., Lippi, G., Bonora, E., Targher, G.

“…Despite the high prevalence and serious clinical implications of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM),…”
Get full text

Association between non-alcoholic fatty liver disease and decreased lung function in adults: A systematic review and meta-analysis by Mantovani, A., Lonardo, A., Vinco, G., Zoppini, G., Lippi, G., Bonora, E., Loomba, R., Tilg, H., Byrne, C.D., Fabbri, L., Targher, G.

“…Recent observational studies assessed the association between non-alcoholic fatty liver disease (NAFLD) and lung function in adults, but the magnitude of this…”
Get full text

Association between PNPLA3rs738409 polymorphism decreased kidney function in postmenopausal type 2 diabetic women with or without non-alcoholic fatty liver disease by Mantovani, A., Zusi, C., Sani, E., Colecchia, A., Lippi, G., Zaza, G.L., Valenti, L., Byrne, C.D., Maffeis, C., Bonora, E., Targher, G.

“…Evidence is emerging that PNPLA3 rs738409 polymorphism (the major genetic variant associated with susceptibility to non-alcoholic fatty liver disease [NAFLD])…”
Get full text

Associations between specific plasma ceramides and severity of coronary-artery stenosis assessed by coronary angiography by Mantovani, A., Bonapace, S., Lunardi, G., Canali, G., Dugo, C., Vinco, G., Calabria, S., Barbieri, E., Laaksonen, R., Bonnet, F., Byrne, C.D., Targher, G.

“…Recent prospective studies have identified distinct plasma ceramides as strong predictors of major adverse cardiovascular events in patients with established…”
Get full text

Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients by Targher, G, Bertolini, L, Chonchol, M, Rodella, S, Zoppini, G, Lippi, G, Zenari, L, Bonora, E

“…Aims/hypothesis Non-alcoholic fatty liver disease (NAFLD) is associated with an increased prevalence of chronic kidney disease (CKD) and retinopathy in…”
Get full text

Psychological distress, self-efficacy and glycemic control in type 2 diabetes by Indelicato, L, Dauriz, M, Santi, L, Bonora, F, Negri, C, Cacciatori, V, Targher, G, Trento, M, Bonora, E

“…Abstract Aim To investigate the association of glycemic control with depression, anxiety, self-efficacy and other diabetes-specific psychological measures in a…”
Get full text

Association between specific plasma ceramides and high-sensitivity C-reactive protein levels in postmenopausal women with type 2 diabetes by Mantovani, A., Altomari, A., Lunardi, G., Bonapace, S., Lippi, G., Bonnet, F., Targher, G.

“…Emerging evidence suggests that specific plasma ceramides are involved in the pathophysiology of cardiovascular disease (CVD) and other inflammation-associated…”
Get full text

Association between increased plasma ceramides and chronic kidney disease in patients with and without ischemic heart disease by Mantovani, A., Lunardi, G., Bonapace, S., Dugo, C., Altomari, A., Molon, G., Conti, A., Bovo, C., Laaksonen, R., Byrne, C.D., Bonnet, F., Targher, G.

“…Plasma levels of certain ceramides are increased in patients with ischemic heart disease (IHD). Many risk factors for IHD are also risk factors for chronic…”
Get full text

Increased prevalence of chronic kidney disease in patients with Type 1 diabetes and non-alcoholic fatty liver by Targher, G., Pichiri, I., Zoppini, G., Trombetta, M., Bonora, E.

“…Diabet. Med. 29, 220–226 (2012) Aims  We determined whether non‐alcoholic fatty liver is associated with an increased prevalence of chronic kidney disease in…”
Get full text

Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study by Mikolasevic, I., Rahelic, D., Turk-Wensween, T., Ruzic, A., Domislovic, V., Hauser, G., Matic, T., Radic-Kristo, D., Krznaric, Z., Radic, M., Filipec Kanizaj, T., Martinovic, M., Jerkic, H., Medjimurec, M., Targher, G.

“…The aim of this study was to investigate whether controlled attenuation parameter (CAP) and liver stiffness measurement (LSM), as assessed by…”
Get full text